Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hospira's Inflectra becomes Canada's first biosimilar

This article was originally published in Scrip

Executive Summary

Hospira has launched its biosimilar version of infliximab, Inflectra, in Canada, making it the first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy in the country. It was approved by Health Canada for the treatment of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and plaque psoriasis. The reference product J&J's Remicade recorded sales of nearly CAN$800m in Canada in 2014. Canada is unusual in that the majority of infliximab infusions take place outside of hospitals. Hospira has developed an in-depth patient assistance program to help provide infusion-clinic access to qualifying patients across Canada, along with numerous other patient services. Inflectra is already available in 26 European countries and Australia. In 2009, Hospira entered into an agreement with South Korean company, Celltrion, to obtain rights to Inflectra in Europe, the US, Canada, Australia and New Zealand.

You may also be interested in...

Catabasis’s Future In Doubt After DMD Phase III Failure

Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.

Novartis Advances Novel Kidney Disease Therapy Iptacopan

Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.

Aptinyx To Forge Ahead With Pivotal PTSD Study

Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts